Neuralstem Inc (CUR)

0.26
0.00 1.10
NASDAQ : Health Care
Prev Close 0.26
Open 0.25
Day Low/High 0.25 / 0.27
52 Wk Low/High 0.24 / 1.96
Volume 211.09K
Avg Volume 626.30K
Exchange NASDAQ
Shares Outstanding 114.86M
Market Cap 29.86M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits At The Radiation Research Society Annual Meeting

Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits At The Radiation Research Society Annual Meeting

NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits

Neuralstem Presented NSI-189 Preclinical Data In Type 1 And Type 2 Diabetes At The Annual Meeting Of The Diabetic Neuropathy Study Group

Neuralstem Presented NSI-189 Preclinical Data In Type 1 And Type 2 Diabetes At The Annual Meeting Of The Diabetic Neuropathy Study Group

NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice

Neuralstem Reports Second Quarter 2016 Results and Provides Business And Clinical Updates

Neuralstem Reports Second Quarter 2016 Results and Provides Business And Clinical Updates

Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman

Neuralstem Announces NSI-189 Shows Enhancement Of Long-Term Potentiation In Vitro

Neuralstem Announces NSI-189 Shows Enhancement Of Long-Term Potentiation In Vitro

Data Contribute to Understanding NSI-189 Mechanism of Action

These 5 Stocks Under $10 Are About to Soar Higher

These 5 Stocks Under $10 Are About to Soar Higher

These under-$10 stocks are ready to move higher from current levels. Here's how to trade them from here.

Neuralstem To Raise $1.08 Million

Neuralstem To Raise $1.08 Million

Neuralstem Announces First Patient Enrolled In Phase 2 Clinical Trial In Major Depressive Disorder

Neuralstem Announces First Patient Enrolled In Phase 2 Clinical Trial In Major Depressive Disorder

Trial Efficacy Endpoints Include Reduction in Depression and Cognition Improvement

IIROC Trade Resumption - CUR

IIROC Trade Resumption - CUR

IIROC Trading Halt - CUR

IIROC Trading Halt - CUR

Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference

Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference

NSI-566 Trial Data Reveals Biological Activity Across Multiple Neurodegenerative Diseases: ALS, Chronic Spinal Cord Injury, and Stroke

Brainstorm Recycles ALS Stem Cell Data to Boost Sagging Stock

Brainstorm Recycles ALS Stem Cell Data to Boost Sagging Stock

A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.

Data For Neuralstem's Novel NSI-189 Molecule In Major Depressive Disorder Published In Molecular Psychiatry

Data For Neuralstem's Novel NSI-189 Molecule In Major Depressive Disorder Published In Molecular Psychiatry

Phase 1b Data Demonstrate Potential of Oral Neurogenesis-based Therapies

Insider Trading Alert - TIPT, VER And CUR Traded By Insiders

Insider Trading Alert - TIPT, VER And CUR Traded By Insiders

Stocks with insider trader activity include TIPT, VER and CUR